RELMADA THERAPEUTICS, INC. — Director's Dealing 2021

Feb 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2021-02-02

Reporting Person: TRAVERSA SERGIO (Director, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-02	Common Stock	M	13281	$3.24	Acquired	88774	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-02	Options to purchase common stock	$3.24	M	13281	Disposed	2027-10-20	Common Stock (13281)	Direct

Footnotes

F1: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.

F2: Not applicable.